Drug intelligence / Profile preview

SI000413

Development stage: Phase 2
Lead developer: Dong-A Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

SI000413 is an orally administered investigational drug developed by Dong-A for the treatment of knee osteoarthritis. It is described as a new herbal formula and has demonstrated anti-inflammatory effects in preclinical models, such as ameliorating collagen-induced arthritis in mice by reducing disease incidence and severity. Clinical trials have been conducted to evaluate its efficacy and safety in patients with knee osteoarthritis.

Beyond the preview

Go deeper on SI000413.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SI000413.

Explore the full profile